Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.
NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disea...
Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024In patients with any PD-L1 expression (...
In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or deat...
KEYNOTE-A18 is the first Phase 3 study of an immunotherapy in combination with CRT to demonstrate a statistically significant...
KEYTRUDA is the first anti-PD-1/L1 therapy in combination with trastuzumab and chemotherapy to demonstrate a statistically si...
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared ...
Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight ne...
